Is gabapentin an appropriate treatment for restless legs syndrome (RLS)?

Gabapentin for Restless Leg Syndrome

Yes, gabapentin is strongly recommended as a first-line treatment for adults with restless legs syndrome (RLS), based on the most recent 2025 American Academy of Sleep Medicine guidelines. 1

Primary Recommendation

The 2025 AASM clinical practice guideline provides a strong recommendation with moderate certainty of evidence for using gabapentin in adults with RLS 1. This places gabapentin among the top-tier treatment options, alongside gabapentin enacarbil and pregabalin, which also received strong recommendations 1.

Key Evidence Hierarchy

The guideline framework prioritizes:

• Gabapentin enacarbil (strong recommendation, moderate certainty) 1
• Gabapentin (strong recommendation, moderate certainty) 1
• Pregabalin (strong recommendation, moderate certainty) 1
• IV ferric carboxymaltose (strong recommendation, moderate certainty) 1

All other pharmacologic agents received either conditional recommendations or recommendations against their standard use.

Clinical Context: Why Gabapentin Over Dopamine Agonists

The 2025 guidelines represent a major shift away from dopamine agonists as first-line therapy. The AASM now suggests against the standard use of:

• Pramipexole (conditional recommendation, moderate certainty) 1
• Ropinirole (conditional recommendation, moderate certainty) 1
• Rotigotine (conditional recommendation, low certainty) 1
• Levodopa (conditional recommendation, very low certainty) 1

The critical caveat: these dopaminergic agents may still be used short-term in patients who prioritize immediate symptom reduction over long-term adverse effects, particularly augmentation 1. Augmentation—the worsening of RLS symptoms with chronic dopaminergic therapy—is the primary reason for this paradigm shift.

Dosing and Practical Implementation

While the FDA label does not specifically list RLS as an approved indication 2, clinical trial data supports:

• Starting dose: 300 mg
• Mean effective dose: 1,855 mg/day (divided doses) 3
• Therapeutic effects: Observable by week 4 at approximately 1,391 mg 3
• Dose range: 300-1,200 mg in clinical studies 4

Evidence of Efficacy

Gabapentin demonstrates benefits across multiple domains:

• Sensory and motor symptoms: Significant reduction on RLS Rating Scale 3
• Periodic leg movements during sleep (PLMS): Significantly reduced PLMS index 3, 5
• Sleep architecture: Increased total sleep time, sleep efficiency, and slow wave sleep; decreased stage 1 sleep 3
• Pain: Patients with painful RLS symptoms benefit most 3

Special Population: End-Stage Renal Disease

For adults with RLS and ESRD, the AASM suggests using gabapentin (conditional recommendation, very low certainty of evidence) 1. This represents one of the few pharmacologic options specifically addressed for this population.

Safety Profile

Common adverse effects from FDA labeling include 2:

• Somnolence/sedation: 19% (vs 9% placebo)
• Dizziness: 17% (vs 7% placebo)
• Ataxia: 13% (vs 6% placebo)

Critical safety warnings 2:

• DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)—can be fatal
• Anaphylaxis and angioedema—may occur after first dose
• Driving impairment—patients should not drive until they assess their response
• CNS depression—particularly when combined with other sedating medications

Comparative Effectiveness

A head-to-head trial showed gabapentin (mean 800 mg) and ropinirole (mean 0.78 mg) provided similarly effective treatment, with both reducing PLMS and improving symptoms 4. However, given the 2025 guideline recommendations against standard dopamine agonist use due to augmentation risk, gabapentin emerges as the preferred option for long-term management.

Clinical Algorithm

For adults with moderate to severe RLS:

1. Check iron status first: Ferritin and transferrin saturation

   • If ferritin ≤75 μg/L: Consider ferrous sulfate with vitamin C (conditional recommendation) 1
   • If appropriate iron parameters met: Consider IV ferric carboxymaltose (strong recommendation) 1

2. Initiate gabapentin (or gabapentin enacarbil or pregabalin):

   • Start 300 mg at bedtime
   • Titrate based on response and tolerability
   • Target effective dose typically 1,200-1,800 mg/day in divided doses

3. Reserve dopamine agonists for:

   • Short-term use only
   • Patients who prioritize immediate symptom relief
   • Patients who understand and accept augmentation risk

4. Alternative options if gabapentin fails or is not tolerated:

   • Pregabalin (strong recommendation) 1
   • Extended-release oxycodone/other opioids (conditional recommendation) 1

Important Caveats

• No augmentation reported with gabapentin—a major advantage over dopaminergic agents 6
• Tolerance develops less commonly compared to dopamine agonists
• Sedation and dizziness are the primary limiting factors
• Renal dosing adjustments required in patients with impaired kidney function
• The FDA-approved gabapentin enacarbil formulation provides more consistent pharmacokinetics but is significantly more expensive than generic gabapentin